CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- PositionPrice-to-book is 0.72×, lower than 95% of its Biotechnology peers (median 2.56×)
- FinancialsAltman Z-Score 6.28: safe zone
- Interpretations9 currently firing — 9
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
2.75%Below 5Y avg (2.98%)
Annual Rate
CNY 0.80Paid annual
Payout Ratio
400.0%High
Payback Period
34.8 yr
Last Ex-Dividend
Jul 9, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
3.71BCNY555.57M · vs all stocks (USD)
Revenue (TTM)
410.36MCNY61.50M · vs all stocks (USD)
Profit Margin
-0.13%vs Biotechnology peers
Beta
0.5860xvs all stocks
52-Week Change
-25.53%vs all stocks
Market Capitalization
3.71BCNY555.57M · vs all stocks (USD)
Enterprise Value
-434.97MCNY-65.19M · vs all stocks (USD)
Price to Sales (TTM)
8.88xvs Biotechnology peers
Price to Book (MRQ)
0.7221xvs Biotechnology peers
Enterprise to Revenue
-1.06xvs Biotechnology peers
Enterprise to EBITDA
-35.19xvs Biotechnology peers
Gross Margin
46.92%vs Biotechnology peers
Profit Margin
-0.13%vs Biotechnology peers
Operating Margin
-1.11%vs Biotechnology peers
Return on Assets (TTM)
-0.34%vs Biotechnology peers
Return on Equity (TTM)
-0.01%vs Biotechnology peers
Revenue (TTM)
410.36MCNY61.50M · vs all stocks (USD)
Revenue per Share (TTM)
3.17CNYUpdated Oct 24, 2026Quarterly Revenue Growth
2.80%vs Biotechnology peers
Gross Profit (TTM)
176.18MCNY26.40M · vs all stocks (USD)
EBITDA (TTM)
109.33MCNY16.39M · vs all stocks (USD)
Net Income (TTM)
-525.94KCNY-78.82K · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
2.80%vs Biotechnology peers
Operating Cash Flow (TTM)
-48.45MCNY-7.26M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-74.89MCNY-11.22M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.8000CNYUpdated Oct 24, 2026Trailing Annual Dividend Yield
2.75%vs all stocks
5-Year Average Dividend Yield
2.98%vs all stocks
Payout Ratio
400.00%vs Biotechnology peers
Minority Interest (Equity)
-4.02MCNYFY2025 · Dec 31, 2025Revenue
451.26MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
259.45MCNYFY2025 · Dec 31, 2025Gross Profit
191.80MCNYFY2025 · Dec 31, 2025Operating Income
-15.30MCNY-2.29M · vs all stocks (USD)
Pre-tax Income
74.87MCNYFY2025 · Dec 31, 2025Income Tax Expense
5.66MCNYFY2025 · Dec 31, 2025Net Income
69.21MCNYFY2025 · Dec 31, 2025EBIT
75.15MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
109.33MCNYFY2025 · Dec 31, 2025Research & Development
78.65MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
46.05MCNYFY2025 · Dec 31, 2025Other Operating Expenses
28.33MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
2.68MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
275.57KCNYFY2025 · Dec 31, 2025EPS (Basic)
0.5500CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.5500CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
126.22MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
126.22MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
69.21MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
211.52KCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
138.12MCNYFY2025 · Dec 31, 2025Free Cash Flow
42.86MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
420.10MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
69.21MCNYFY2025 · Dec 31, 2025Other Non-cash Items
40.27MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
20.13MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
8.51MCNYFY2025 · Dec 31, 2025Capital Expenditures
-95.26MCNYFY2025 · Dec 31, 2025Purchase of Investments
-10.32BCNYFY2025 · Dec 31, 2025Sale of Investments
10.69BCNYFY2025 · Dec 31, 2025Other Investing Activity
-157.90MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
117.89MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-280.00KCNYFY2025 · Dec 31, 2025Common Dividends Paid
-101.67MCNYFY2025 · Dec 31, 2025Other Financing Charges
-4.06MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-106.01MCNYFY2025 · Dec 31, 2025Shares Outstanding
127.08MSharesUpdated Oct 24, 2026Float Shares
32.30MSharesUpdated Oct 24, 2026% Held by Insiders
75.89%vs all stocks
% Held by Institutions
2.09%vs all stocks
Total Cash (MRQ)
4.21BCNY630.72M · vs all stocks (USD)
Total Cash per Share (MRQ)
33.29CNYUpdated Oct 24, 2026Total Debt (MRQ)
145.67MCNY21.83M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0290xvs Biotechnology peers
Current Ratio (MRQ)
7.40xvs Biotechnology peers
Book Value per Share (MRQ)
39.73CNYUpdated Oct 24, 2026Total Assets
5.68BCNY850.75M · vs all stocks (USD)
Total Current Assets
4.59BCNYFY2025 · Dec 31, 2025Total Liabilities
515.98MCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.08BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
78.84MCNYFY2025 · Dec 31, 2025Total Current Liabilities
437.14MCNYFY2025 · Dec 31, 2025Cash
423.52MCNYFY2025 · Dec 31, 2025Cash Equivalents
144.75MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
568.27MCNYFY2025 · Dec 31, 2025Other Short-term Investments
1.31BCNYFY2025 · Dec 31, 2025Accounts Receivable
187.06MCNYFY2025 · Dec 31, 2025Inventory
133.34MCNYFY2025 · Dec 31, 2025Accounts Payable
382.91MCNYFY2025 · Dec 31, 2025Short-term Debt
3.44MCNYFY2025 · Dec 31, 2025Other Current Liabilities
539.03KCNYFY2025 · Dec 31, 2025Long-term Debt
2.11MCNYFY2025 · Dec 31, 2025Common Stock (Book)
127.08MCNYFY2025 · Dec 31, 2025Retained Earnings
3.92BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
5.16BCNY773.42M · vs all stocks (USD)
52-Week Low
26.88CNYUpdated Oct 24, 202652-Week High
45.00CNYUpdated Oct 24, 202652-Week Change
-25.53%vs all stocks
Beta
0.5860xvs all stocks
50-Day MA
29.67CNYUpdated Oct 24, 2026200-Day MA
34.04CNYUpdated Oct 24, 2026Avg 10-Day Volume
456.87KSharesUpdated Oct 24, 2026Avg 30-Day Volume
528.94KSharesUpdated Oct 24, 2026Diluted EPS (TTM)
0.5500CNYUpdated Oct 24, 20269 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Diagnostic
Debt Falling While Share Count Rises
Debt has fallen for four years while the share count rose over eight.
Reads
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
Retained Earnings Heavy With Elevated Payout
Profits kept in the business fund much of what it owns, and it now pays out most of what it earns.
Reads
How does this company use capital?
Cash Backing With OCF Coverage And Cash Near Total Debt
Cash on hand covers most or all of its total debt, and cash flow matches reported earnings.
Reads
Cash-Flow Ratios Elevated
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
How is this stock valued?
Close Below 40W SMA With Profitability
The price sits below its 40-week average, on three profitable years and cash above profit.
Reads
Down-Close Streak With Profitability
A run of down weeks on a company profitable three years running and funded by equity.
Reads
High Retained Earnings With Profitability And Equity
Profits kept in the business fund much of what it owns, after five straight profitable years.
Reads
Price Below Mean With Profitability And Equity
Price sits well below its yearly mean, profitable three years, and its equity ratio is high for its industry.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Price-to-book is 0.72×, lower than 95% of its Biotechnology peers (median 2.56×)Notable
Price-to-book: 0.72Industry median: 2.56Industry P5: 0.82Peers compared: 255
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.47Profit Margin: -0.00
Financial Health
Altman Z-Score 6.28: safe zoneNotable
Altman Z-Score: 6.28
High earnings qualityNotable
Earnings Quality Score: 0.51
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Beijing Scitop Bio-Tech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
476830
Tier 1ProductionApproval-Gated PipelineRule
Aclaris Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Tibet Weixinkang Medicine Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shandong Wohua Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Hainan Shuangcheng Pharmaceuticals Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Henan Taloph Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Beijing Science Sun Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Anteris Technologies Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Puma Biotechnology Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Zhejiang Cayi Vacuum Container Co., Ltd.
7 interpretationsHigh Retained Earnings With Profitability And EquityCash-Flow Ratios ElevatedClose Below 40W SMA With ProfitabilityDown-Close Streak With ProfitabilityRetained Earnings Heavy With Elevated PayoutPrice Below Mean With Profitability And EquityCash Backing With OCF Coverage And Cash Near Total Debt
Shenzhen Friendcom Technology Co., Ltd.
6 interpretationsHigh Retained Earnings With Profitability And EquityClose Below 40W SMA With ProfitabilityDown-Close Streak With ProfitabilityRetained Earnings Heavy With Elevated PayoutPrice Below Mean With Profitability And EquityCash Backing With OCF Coverage And Cash Near Total Debt
Shenzhen Keanda Electronic Co., Ltd.
7 interpretationsHigh Retained Earnings With Profitability And EquityCash-Flow Ratios ElevatedClose Below 40W SMA With ProfitabilityDown-Close Streak With ProfitabilityRetained Earnings Heavy With Elevated PayoutPrice Below Mean With Profitability And EquityCash Backing With OCF Coverage And Cash Near Total Debt